What is Nimble Science?
Nimble Science is a pioneer in gastrointestinal diagnostics, primarily recognized for its SIMBA GI Platform. This innovative technology facilitates the collection of multi-omic datasets directly from the small intestine, providing researchers and clinicians with unprecedented visibility into the human microbiome. By bridging the gap between complex biological data and actionable therapeutic insights, the company serves as a critical partner for biopharma entities focused on microbiome-based treatments and fecal transplant validation. Their market position is defined by a unique ability to capture high-fidelity samples that were previously inaccessible, thereby setting a new standard for gastrointestinal health research and personalized medicine.
How much funding has Nimble Science raised?
Nimble Science has raised a total of $2M across 1 funding round:
Other Financing Round
$2M
Other Financing Round (2023): $2M with participation from Threshold Impact, Fusion Fund, and Bluesky Equities
Key Investors in Nimble Science
Threshold Impact
ThresholdImpact is a venture firm focused on sustainable and profitable impact investing across technology, medical innovations, and social entrepreneurship.
Fusion Fund
Fusion Fund specializes in backing early-stage startups that leverage technical or data advantages, particularly within the healthcare and enterprise AI sectors.
Bluesky Equities
Bluesky Equities is a private investment management firm that maintains a long-term perspective on holdings across energy, technology, and venture capital.
What's next for Nimble Science?
With the recent infusion of capital, Nimble Science is poised to transition from its current development phase into a period of aggressive commercial scaling. The strategic roadmap likely involves expanding the deployment of the SIMBA GI Platform to support larger clinical trials and deepening partnerships with global nutrition and pharmaceutical leaders. As the company continues to refine its multi-omic analytical capabilities, it is expected to play a pivotal role in the evolution of therapeutic approaches for chronic gastrointestinal conditions. The focus will remain on enhancing data throughput and integrating these insights into broader health outcome frameworks, ensuring that Nimble Science remains at the forefront of the rapidly evolving microbiome diagnostics landscape.
See full Nimble Science company page
